Pall Acquires Bioreactor Firm
ATMI Life Sciences product lines include biomixers and high–cell density bioreactors. In 2012, ATMI Life Sciences sales increased 8.7% to $41.6 million and grew 20% excluding the impact of foreign exchange and license settlements. Operating loss improved 31.7% to $4.1 million, and gross profit margin was 34.4%.
Port Washington, NY 12/23/13; Danbury, CT 12/23/13—Filtration and separation firm Pall has agreed to acquire ATMI Life Sciences from ATMI, a provider of specialty semiconductor materials, for $185 million. ATMI Life Sciences provides single-use process systems and consumables for the pharmaceutical and biopharmaceutical industries. “This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,” stated Pall Chairman and CEO Larry Kingsley. Pall expects the acquisition to add $20–$30 million in revenue for the balance of fiscal 2014 and to be $0.05–$0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis.
